Acuity Pharmaceuticals said this week that data from a recently completed primate study of Cand5, its RNAi treatment for age-related macular degeneration, indicate that the drug is both safe and effective.
The company has also scheduled a meeting with US regulators to discuss the details of filing an investigational new drug application for Cand5, RNAi News has learned.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
